The major challenge in castration-resistant prostate cancer (CRPC) remains the ability to predict the clinical responses to improve patient selection for appropriate treatments. The finding that androgen deprivation therapy (ADT) induces alterations in the androgen receptor (AR) transcriptional program by AR coregulators activity in a context-dependent manner, offers the opportunity for identifying signatures discriminating different clinical states of prostate cancer (PCa) progression. Gel electrophoretic analyses combined with western blot showed that, in androgen-dependent PCa and CRPC in vitro models, the subcellular distribution of spliced and serine-phosphorylated heterogeneous nuclear ribonucleoprotein K (hnRNP K) isoforms can be ass...
Castration-resistant prostate cancer (CRPC) is defined by resistance of the tumor to androgen depriv...
Abstract Background Prostate cancer (PCa), the second most common cancer affecting men worldwide, sh...
Prostate cancer (PCa) progression is regulated by the androgen receptor (AR); however, patients unde...
The major challenge in castration-resistant prostate cancer (CRPC) remains the ability to predict th...
The major challenge in castration-resistant prostate cancer (CRPC) remains the ability to predict th...
<div><p>The androgen receptor (AR) plays a central role in the development and progression of prosta...
The androgen receptor (AR) plays a central role in the development and progression of prostate cance...
The androgen receptor (AR) regulates prostate cell growth in man, and prostate cancer is the commone...
We previously reported that AR phosphorylation at serine 213 was associated with poor outcome and ma...
SummaryThe androgen receptor (AR) regulates prostate cell growth in man, and prostate cancer is the ...
Identifying the biological change from hormone-naïve prostate cancer to castration-resistant prostat...
Abstract Background The androgen receptor (AR) plays critical roles in both androgen-dependent and c...
Hormonal therapies targeting androgen receptor (AR) are effective in prostate cancer (PCa), but ofte...
Hormonal therapies targeting androgen receptor (AR) are effective in prostate cancer (PCa), but ofte...
SummaryThe androgen receptor (AR) regulates prostate cell growth in man, and prostate cancer is the ...
Castration-resistant prostate cancer (CRPC) is defined by resistance of the tumor to androgen depriv...
Abstract Background Prostate cancer (PCa), the second most common cancer affecting men worldwide, sh...
Prostate cancer (PCa) progression is regulated by the androgen receptor (AR); however, patients unde...
The major challenge in castration-resistant prostate cancer (CRPC) remains the ability to predict th...
The major challenge in castration-resistant prostate cancer (CRPC) remains the ability to predict th...
<div><p>The androgen receptor (AR) plays a central role in the development and progression of prosta...
The androgen receptor (AR) plays a central role in the development and progression of prostate cance...
The androgen receptor (AR) regulates prostate cell growth in man, and prostate cancer is the commone...
We previously reported that AR phosphorylation at serine 213 was associated with poor outcome and ma...
SummaryThe androgen receptor (AR) regulates prostate cell growth in man, and prostate cancer is the ...
Identifying the biological change from hormone-naïve prostate cancer to castration-resistant prostat...
Abstract Background The androgen receptor (AR) plays critical roles in both androgen-dependent and c...
Hormonal therapies targeting androgen receptor (AR) are effective in prostate cancer (PCa), but ofte...
Hormonal therapies targeting androgen receptor (AR) are effective in prostate cancer (PCa), but ofte...
SummaryThe androgen receptor (AR) regulates prostate cell growth in man, and prostate cancer is the ...
Castration-resistant prostate cancer (CRPC) is defined by resistance of the tumor to androgen depriv...
Abstract Background Prostate cancer (PCa), the second most common cancer affecting men worldwide, sh...
Prostate cancer (PCa) progression is regulated by the androgen receptor (AR); however, patients unde...